ANALYSIS OF THE COST PER RESPONDER OF BIOLOGICAL TREATMENTS FOR MODERATE TO SEVERE PSORIASIS IN ARGENTINA

被引：0
|
作者：
Kanevsky, D. [1 ]
Rodriguez, M. F. [1 ]
Suarez Ordonez, S. [1 ]
Elgart, J. [2 ]
Mazzuoccolo, L. D. [3 ]
机构：
[1] Abbvie, Buenos Aires, DF, Argentina
[2] UNLP, CONICET, CENEXA, Ctr Endocrinol Expt & Aplicada, La Plata, Buenos Aires, Argentina
[3] Hosp Italiano Buenos Aires, Buenos Aires, DF, Argentina
来源：
VALUE IN HEALTH | 2020年 / 23卷
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PMU23
引用
收藏
页码：S607 / S607
页数：1
相关论文
共 50 条
  • [1] Cost per responder analysis of ustekinumab and etanercept for moderate to severe plaque psoriasis
    Martin, Silas
    Feldman, Steven R.
    Augustin, Matthias
    Szapary, Philippe
    Schenkel, Brad
    JOURNAL OF DERMATOLOGICAL TREATMENT, 2011, 22 (03) : 138 - 143
  • [2] SECUKINUMAB AS FIRST BIOLOGIC TREATMENT: A COST PER RESPONDER ANALYSIS COMPARED WITH LICENSED BIOLOGICS, FOR MODERATE TO SEVERE PSORIASIS IN ARGENTINA
    Bianculli, P. M.
    Salibe, M.
    Peirano, I
    Gilloteau, I
    Graham, C.
    VALUE IN HEALTH, 2018, 21 : S428 - S428
  • [3] Numbers needed to treat and costs per responder for novel treatments of moderate to severe psoriasis
    Armstrong, April
    Betts, Keith
    Li, Junlong
    Sundaram, Murali
    Wu, Eric
    Signorovitch, James
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2016, 74 (05) : AB261 - AB261
  • [4] MODELLING AVERAGE COST AND COST-PER-RESPONDER FOR BIOLOGICAL TREATMENTS FOR MODERATE-TO-SEVERE PLAQUE PSORIASIS WITH DOSE ESCALATION AND REAL-WORLD DRUG SURVIVAL
    Ziegler, F.
    Apol, E.
    Egeberg, A.
    VALUE IN HEALTH, 2018, 21 : S453 - S453
  • [5] COST PER RESPONDER ANALYSIS OF BRODALUMAB COMPARED WITH USTEKINUMAB IN THE TREATMENT OF MODERATE-TO-SEVERE PLAQUE PSORIASIS IN CANADA
    Schembri, J.
    Barbeau, M.
    Gaudet, V
    VALUE IN HEALTH, 2018, 21 : S425 - S425
  • [6] COST PER RESPONDER ANALYSIS OF METHOTREXATE VERSUS OTHER THERAPIES IN THE TREATMENT OF MODERATE TO SEVERE PLAQUE PSORIASIS IN ITALY
    Pompilio, G.
    Integlia, D.
    Usala, M.
    VALUE IN HEALTH, 2022, 25 (12) : S157 - S157
  • [7] Cost per responder analysis of guselkumab versus targeted therapies in the treatment of moderate to severe plaque psoriasis in Germany
    Augustin, Matthias
    Wirth, Daniel
    Mahlich, Joerg
    Pepper, Alicia N.
    Druchok, Cheryl
    JOURNAL OF DERMATOLOGICAL TREATMENT, 2022, 33 (02) : 976 - 982
  • [8] Cost Per Additional Responder Associated With Ixekizumab and Etanercept in the Treatment of Moderate-to-Severe Psoriasis
    Feldman, Steven R.
    Foster, Shonda A.
    Zhu, Baojin
    Burge, Russel
    Al Sawah, Sarah
    Goldblum, Orin M.
    JOURNAL OF DRUGS IN DERMATOLOGY, 2017, 16 (12) : 1246 - 1252
  • [9] Cost per responder of apremilast versus etanercept, adalimumab, and ustekinumab in patients with moderate to severe psoriasis
    Feldman, Steven R.
    Tencer, Tom
    Clancy, Zoe
    Zhang, Frank
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2015, 72 (05) : AB229 - AB229
  • [10] Number needed to treat and cost per responder for biologic therapies for the treatment of moderate to severe psoriasis
    Langley, Richard G.
    Signorovitch, James
    Wang, Ke
    Betts, Keith A.
    Sundaram, Murali
    Mulani, Parvez
    Yan, Sherry
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2014, 70 (05) : AB2 - AB2
12345